Neurogen Biomarking has entered a collaboration to adopt Tasso’s needle-free blood collection technology into its at-home Alzheimer’s testing platform.
The collaboration will see Neurogen’s brain health assessment system integrate Tasso’s sample collection devices.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to Tasso, its technology could help broaden access to Alzheimer’s biomarker testing by providing a non-invasive experience.
As part of Neurogen’s offering, a blood biomarker test will be used alongside a digital cognitive evaluation to aid in identifying those who might be at increased risk for Alzheimer’s.
Licensed professionals visit the patients at their homes to collect samples using both the Tasso+ device and conventional methods.
These samples are said to be processed in certified labs, with results reviewed by neurologists through telehealth appointments, offering patients guidance on possible next steps.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTasso co-founder and CEO Ben Casavant said: “Making blood collection more patient-centric is key to ensuring everyone who needs testing has access to it.
“Our virtually painless collection technology offers individuals a simple and comfortable way to provide blood samples. We’re pleased that Neurogen has chosen to include our device as part of their service model.”
Neurogen retains the intellectual property rights for its blood-based biomarker test.
The company claims to provide the inaugural at-home blood test for phosphorylated tau (P-tau217) combined with digital cognitive testing and telehealth outcomes guided by neurologists.
Its online platform, which enables at-home collection for those concerned about memory issues, is in beta testing at present.
Neurogen Biomarking CEO and founder Dr Rany Aburashed said: “Neurogen is on a fast-track to becoming the global entry point for early evaluation of Alzheimer’s-related biomarkers.
“The addition of Tasso’s technology to our ecosystem creates a streamlined, scalable at-home experience designed to make Alzheimer’s-related testing more accessible.”
In August 2025, Tasso formed a partnership with SheMed, a women’s health company, to offer at-home blood testing for weight loss treatments in the UK.
